目的:眼睑退缩是甲状腺相关眼病(TAO)最常见的症状之一,这可能会引发各种并发症,如眼睛干涩,暴露性角膜病变,和化妆品问题。局部皮质类固醇注射,比如曲安奈德,已被提议作为TAO的治疗选择。对于不耐受大剂量甲基强的松龙的全身效应的患者,这种方法可能是一种有利的替代方法。然而,这种干预措施的疗效尚不明确.因此,我们的综述旨在评估曲安奈德注射液减少眼睑回缩的疗效.
方法:本系统评价遵循系统评价和荟萃分析(PRISMA)指南的首选报告项目,并在三个数据库中进行(PubMed,科学直接,和ProQuest)。这篇综述包括使用局部注射曲安奈德治疗甲状腺相关眼病的研究。这篇评论感兴趣的结果是眼睑缩回参数。
结果:从六项研究来看,共纳入392例患者.所有研究均显示接受曲安奈德治疗的患者的眼睑回缩有显着改善(所有p<0.05),如ΔMRD所示(1个月为-0.93mm,3个月为-1.38mm),ΔMLD(-1.98mm,6个月),和Δ睑裂高度(1个月-1.68)。大多数研究表明,在治疗的第一个月,眼睑回缩迅速改善。
结论:曲安奈德注射液是治疗甲状腺相关眼病眼睑回缩的有效方法。
OBJECTIVE: Lid retraction is one of the most common symptoms of Thyroid-Associated Ophthalmopathy (TAO), which potentially precipitates various complications, such as dry eyes, exposure keratopathy, and cosmetic concerns. Local corticosteroid injections, such as triamcinolone, have been proposed as a choice of treatment for TAO. This approach may be a favorable alternative for patients intolerant to the systemic effects of high-dose methylprednisolone. However, the efficacy of this intervention remains unestablished. Hence, our
review aims to evaluate the efficacy of triamcinolone injection in reducing lid retraction.
METHODS: This systematic
review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guideline and was conducted in three databases (PubMed, Science Direct, and ProQuest). This
review included studies that use local triamcinolone injections for patients with thyroid-associated ophthalmopathy. The outcome of interest in this
review is lid retraction parameters.
RESULTS: From six studies, a total of 392 patients were included. All studies showed significant improvement in lid retraction in the patient who received triamcinolone (all p < 0.05) as shown by ΔMRD (-0.93 mm in 1 month and -1.38 mm in 3 months), ΔMLD (-1.98 mm at 6 months), and Δpalpebral fissure height (-1.68 in 1 month). The majority of studies showed rapid improvement in lid retraction in the first month of therapy.
CONCLUSIONS: Triamcinolone injection is an effective therapy for lid retraction related to thyroid-associated ophthalmopathy.